KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Gross Profit: 2019-2024

Historic Gross Profit for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $13.6 million.

  • Recursion Pharmaceuticals' Gross Profit fell 167.93% to -$9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.8 million, marking a year-over-year decrease of 212.79%. This contributed to the annual value of $13.6 million for FY2024, which is 584.15% up from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Gross Profit is $13.6 million, which was up 584.15% from $2.0 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Gross Profit ranged from a high of $13.6 million in FY2024 and a low of -$8.4 million during FY2022.
  • Moreover, its 3-year median value for Gross Profit was $2.0 million (2023), whereas its average is $2.4 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Gross Profit tumbled by 182.85% in 2022, and later soared by 584.15% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Gross Profit (Yearly) stood at $4.0 million in 2020, then spiked by 156.89% to $10.2 million in 2021, then tumbled by 182.85% to -$8.4 million in 2022, then surged by 123.58% to $2.0 million in 2023, then surged by 584.15% to $13.6 million in 2024.